Linked Life Data

19840524

Source:http://linkedlifedata.com/resource/pubmed/id/19840524

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
2009-10-20
pubmed:abstractText
Novel imaging modalities continue to emerge in medicine, and the advent of (18)F-fluorodeoxyglucose-positron emission tomography (FDG-PET) has had a significant impact in the imaging of gynecologic malignancies. In cervical cancer, FDG-PET has excellent sensitivity and specificity for evaluation of initial disease, as well as assessment of post-treatment response and long-term surveillance. In ovarian cancer, FDG-PET can be a useful tool in assessing recurrent disease, especially in the setting of a rising cancer antigen-125 with a negative or equivocal CT or MRI. In uterine cancer, FDG-PET has been investigated in evaluating the extent of disease including nodal metastases, and in assessing recurrence. This article reviews novel imaging modalities in gynecologic cancer, with a special focus on FDG-PET/CT.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
1534-6269
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
11
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
466-72
pubmed:meshHeading
pubmed:year
2009
pubmed:articleTitle
Novel imaging modalities in gynecologic cancer.
pubmed:affiliation
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Washington University School of Medicine, Box 8064, Saint Louis, MO 63110, USA.
pubmed:publicationType
Journal Article, Review